Comparative Effects of 30 Antipsychotics on Risk of Catatonia: An Analysis of the WHO Pharmacovigilance Database

Julien Da Costa, MD^a,b ; Etienne Very, MD, MSc^c,d ; Vanessa Rousseau, PhD^a,e ; Jordan Virolle, MD^c ; Maximilien Redon, MD^c ; Simon Taïb, MD^c,d ; Alexis Revet, MD, PhD^a,f ; François Montastruc, MD, PhD^a,e

J Clin Psychiatry 2023;84(1):21m14238

ABSTRACT

Objective: Catatonia is a life-threatening psychomotor syndrome that occurs in approximately 10% of patients with acute psychiatric illnesses. Although some case reports have argued that first generation antipsychotics (FGAs) are more likely to induce catatonia than second generation antipsychotics (SGAs), no large observational study has confirmed this hypothesis. We investigated whether FGAs were associated with an increased risk of reporting catatonia when compared with SGAs.

Methods: A pharmacovigilance study was performed within VigiBase to compare the cases of catatonia syndromes reported in patients exposed to FGAs with those reported in patients exposed to SGAs. This approach is similar in concept to case-control study, but adapted to a pharmacovigilance database, and allows the estimation of reporting odds ratios (RORs) with 95% confidence intervals.

Results: We identified 60,443 adverse effects reported in patients who received FGAs and 253,067 adverse effects reported in patients treated with SGAs. Compared with SGAs, the use of FGAs was associated with an increased risk of reporting catatonia syndromes (ROR = 2.2; 95% CI, 2.0–2.3). Consistent results were observed when the analysis was restricted to reports generated from physicians, reports from the US, and reports with the highest completeness score. The highest RORs were found for molindone (6.0; 95% CI, 3.1–10.4) and haloperidol (3.8; 95% CI, 3.5–4.0).

Conclusions: In this large pharmacovigilance study of patients exposed to antipsychotics, the use of FGAs was associated with an increased risk of reporting catatonia syndromes compared to the use of SGAs. This increased risk is consistent with the pharmacodynamic hypothesis of antipsychotic-induced catatonia. Our results warrant replication in population-based studies.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (31)

Dhossche DM, Wachtel LE, Goetz M, et al. Catatonia in psychiatric illnesses. In: Fatemi SH, Clayton PJ, eds. The Medical Basis of Psychiatry. Springer New York; 2016:517–535.
Solmi M, Pigato GG, Roiter B, et al. Prevalence of catatonia and its moderators in clinical samples: results from a meta-analysis and meta-regression analysis. Schizophr Bull. 2018;44(5):1133–1150. PubMed CrossRef
Sienaert P, Dhossche DM, Gazdag G. Adult catatonia: etiopathogenesis, diagnosis and treatment. Neuropsychiatry (London). 2013;3(4):391–399. CrossRef
Fink M, Shorter E, Taylor MA. Catatonia is not schizophrenia: Kraepelin’s error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophr Bull. 2010;36(2):314–320. PubMed CrossRef
Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull. 2010;36(2):239–242. PubMed CrossRef
White DAC. Catatonia and the neuroleptic malignant syndrome: a single entity? Br J Psychiatry. 1992;161(4):558–560. PubMed CrossRef
Lee JWY. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol. 2010;30(1):3–10. PubMed CrossRef
Sienaert P, van Harten P, Rhebergen D. The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia. Handb Clin Neurol. 2019;165:41a5–428. PubMed CrossRef
Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870–876. PubMed CrossRef
Tabbane K, Halayem S, Joober R. Clozapine for the management of persistent catatonia. J Psychiatry Neurosci. 2016;41(6):E81–E82. PubMed CrossRef
Tsai JH, Yang P, Yen JY, et al. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy. 2005;25(8):1156–1159. PubMed CrossRef
Van Den Eede F, Van Hecke J, Van Dalfsen A, et al. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry. 2005;20(5-6):422–429. PubMed CrossRef
Faillie JL. Case-non case studies: principles, methods, bias and interpretation [Les études cas–non cas: principe, méthodes, biais et interpretations]. Therapie. 2018;73(3):247–255. PubMed CrossRef
Khouri C, Petit C, Tod M, et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol. 2021;134:14–21. PubMed CrossRef
Bergvall T, Norén GN, Lindquist M. VigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65–77. PubMed CrossRef
Breen J, Hare DJ. The nature and prevalence of catatonic symptoms in young people with autism. J Intellect Disabil Res. 2017;61(6):580–593. PubMed CrossRef
Wing L, Shah A. Catatonia in autistic spectrum disorders. Br J Psychiatry. 2000;176(4):357–362. PubMed CrossRef
Lao KSJ, Zhao J, Blais JE, et al. Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study. CNS Drugs. 2020;34(11):1165–1175. PubMed CrossRef
Schneider M, Regente J, Greiner T, et al. Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):23–33. PubMed CrossRef
Nguyen TTH, Pariente A, Montastruc JL, et al. An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017;83(3):612–622. PubMed CrossRef
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. PubMed CrossRef
Reynolds GP. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatr Scand suppl. 1994;380(s380):36–40. PubMed CrossRef
Hirjak D, Kubera KM, Wolf RC, et al. Going back to Kahlbaum’s psychomotor (and GABAergic) origins: is catatonia more than just a motor and dopaminergic syndrome. Schizophr Bull. 2020;46(2)272–285. PubMed CrossRef
Caroff SN, ed. Catatonia: From Psychopathology to Neurobiology. 1st ed. American Psychiatric Pub; 2004.
Haroche A, Rogers J, Plaze M, et al. Brain imaging in catatonia: systematic review and directions for future research. Psychol Med. 2020;50(10):1585–1597. PubMed CrossRef
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396. PubMed CrossRef
Bégaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288(13):1588. PubMed CrossRef
Caster O, Aoki Y, Gattepaille LM, et al. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020;43(5):479–487. PubMed CrossRef
Pierfitte C, Bégaud B, Lagnaoui R, et al. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47(3):329–331. PubMed CrossRef
Rogers JP, Pollak TA, Blackman G, et al. Catatonia and the immune system: a review. Lancet Psychiatry. 2019;6(7):620–630. PubMed CrossRef
van der Heijden FMMA, Tuinier S, Arts NJM, et al. Catatonia: disappeared or under-diagnosed? Psychopathology. 2005;38(1):3–8. PubMed CrossRef